Product Information

VYVANSE 40 MG CHEWABLE TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3416 per EA under NDC 59417011801. Its NADAC has been published 380 times since Mar 20, 2019.

The High Outlier badge above means this manufacturer's average price in the LISDEXAMFETAMINE DIMESYLATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

VYVANSE 40 MG CHEWABLE TABLET

LISDEXAMFETAMINE DIMESYLATE
$12.3416per EA
High Outlier
DEA Schedule CII

Strength

40 mg/1

NDC

59417011801

Classification

Brand

Dosage Form

TABLET, CHEWABLE

Route

ORAL

Last Updated

6/17/2026

Active Ingredients

LISDEXAMFETAMINE DIMESYLATE

Approval Type

New Drug (NDA)

FDA Application

NDA208510

On Market Since

1/28/2017

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulation

Price Statistics

The NADAC for VYVANSE 40 MG CHEWABLE TABLET has been published 380 times since Mar 20, 2019, and over the history we have for it it has risen 29.7%. The table below summarizes its recorded NADAC range and movement.

Current price$12.3416 per EA
All-time high$12.4242 (Jul 10, 2024)
All-time low$9.5170 (Mar 20, 2019)
52-week high$12.3711
52-week low$12.3402
Median price$11.2342
Average price$11.3176
Largest weekly change+5.0% (Jan 13, 2021)
Weeks tracked380
Tracking sinceMar 20, 2019

Price History

1W

0.0%

1M

+0.0%

3M

-0.0%

6M

-0.1%

1Y

-0.2%

3Y

+4.6%

5Y

+15.5%

All

+29.7%

Generic Alternatives

The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 77% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of VYVANSE 40 MG CHEWABLE TABLET?

The current National Average Drug Acquisition Cost (NADAC) for VYVANSE 40 MG CHEWABLE TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $12.3416 per EA (NDC 59417011801), effective Jun 24, 2026.

How has the price of VYVANSE 40 MG CHEWABLE TABLET changed over time?

Over the history we have for it, the NADAC for VYVANSE 40 MG CHEWABLE TABLET has risen 29.7%. It has been tracked across 380 weekly CMS publications since Mar 20, 2019.

What are the highest and lowest recorded NADAC prices for VYVANSE 40 MG CHEWABLE TABLET?

Since Mar 20, 2019, the NADAC for VYVANSE 40 MG CHEWABLE TABLET has ranged from a low of $9.5170 (Mar 20, 2019) to a high of $12.4242 (Jul 10, 2024), with a median of $11.2342 per EA.

Are there cheaper alternatives to VYVANSE 40 MG CHEWABLE TABLET?

Yes. 3 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, LISDEXAMFETAMINE 40 MG CAPSULE, is $2.8168 per EA — about 77% below VYVANSE 40 MG CHEWABLE TABLET.

Who manufactures VYVANSE 40 MG CHEWABLE TABLET?

VYVANSE 40 MG CHEWABLE TABLET (NDC 59417011801) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.